onasemnogene abeparvovec clinical trials

Long-term Follow-up of Patients With Spinal Muscular Atrophy Treated With OAV101 in Clinical Trials

This study looks at the long-term safety and effects of the medicine onasemnogene abeparvovec (OAV101) for Spinal Muscular Atrophy (SMA). It follows people who previously took part in an OAV101 trial for five years to see how they are doing.